Journal: Cancers

Article Title: First-Line Combination of R-CHOP with the PDE4 Inhibitor Roflumilast for High-Risk DLBCL.

doi: 10.3390/cancers16223857

Figure Lengend Snippet: Figure 1. VEGF-A quantification and PI3K activity in DLBCL patients treated with SOC R-CHOP or Ro+R-CHOP. (A) Left to right, fold change in urinary VEGF-A levels from baseline (before cycle 1—C1) to after the completion of two or five treatment cycles (at the start of cycle 3 or cycle 6, C3 or C6); nine Ro+R-CHOP- and six or seven R-CHOP-treated patients were included in these analyses. (B) Left to right, fold change in urinary VEGF-A levels from baseline (before cycle 1—C1) to after the completion of two or five treatment cycles (at the start of cycle 3 or cycle, C3 or C6); only non-GCB DLBCL patients and complete responders (CRs) were included in these analyses, with five Ro+R-CHOP- and three R-CHOP-treated patients. (C) Fold change in PI3K activity measured in the PBMCs of patients treated with Ro+R-CHOP, comparing the baseline (before cycle 1—C1) to after the completion of two treatment cycles (at the start of cycle 3—C3). Three patients with PR-R/R (partial responder–relapsed/refractory) who died of their disease are compared to four patients who achieved CR and remain free of disease (materials were not available for UPN#1, a complete responder and long-term survivor). (D) Fold change in PI3K activity measured in the PBMCs of patients treated with SOC R-CHOP, comparing the baseline (before cycle 1—C1) to after the completion of two treatment cycles (at the start of cycle 3—C3). Two patients in this series did not reach CR, and materials were not available for one of them. Data are mean ± SD. All data points quantified are shown (three replicates for each patient); p values are from two-sided Student’s t-test, * < 0.05, *** < 0.001, **** < 0.0001.

Article Snippet: The urinary VEGF-A levels were measured using the AuthentiKineTM human VEGF ELISA kit (Proteintech Group Inc., Rosemont, IL, USA), according to the manufacturer’s instructions.

Techniques: Activity Assay

Journal: International Journal of Molecular Sciences

Article Title: Transplantation of Chemical Compound-Induced Cells from Human Fibroblasts Improves Locomotor Recovery in a Spinal Cord Injury Rat Model

doi: 10.3390/ijms241813853

Figure Lengend Snippet: Immature CiN cells secrete HGF and IL-1RN at the protein level. ( A , B ) ELISA analysis revealed that CiN cells secrete HGF and IL-1RN, whereas fibroblasts and control cells do not. ( C ) A schematic diagram of cytokines with elevated gene expression in immature CiN cells and their expected effects on SCI.

Article Snippet: The ELISA was performed using AuthentiKineTM Human HGF ELISA Kit (PGI-KE00168-1, Proteintech, Rosemont, IL, USA) for HGF and Human IL-1ra/IL-1F3 Quantikine ELISA Kit (DRA00B, R&D SYSTEMS, Minneapolis, MN, USA) for IL-1RN, according to the manufacturer’s instructions, respectively.

Techniques: Enzyme-linked Immunosorbent Assay, Control, Gene Expression